Emulsion for non-invasive blood-brain barrier transient opening and controlled drug release into the brain

Patent metadata

Field	Value
Publication number	US-2025186343-A1
Application number	US-202318846190-A
Country	US
Kind code	A1
Filing date	Mar 9, 2023
Priority date	Mar 11, 2022
Publication date	Jun 12, 2025
Grant date	—

Abstract

An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.

First claim

1 . An emulsion comprising:
a first discontinuous phase comprising first droplets including at least one first surfactant, and at least one first fluorocarbon, the first droplets having a first diameter of more than 100 nm; a second discontinuous phase comprising second droplets including at least one second surfactant, at least one drug, and at least one solvent, the second droplets having a second diameter of no more than 100 nm; and a continuous aqueous phase.

2 . The emulsion of claim 1 , wherein the first diameter and the second diameter are measured by dynamic light scattering (DLS).

3 . The emulsion of claim 1 , wherein:
the at least one first fluorocarbon has a boiling point of no more than 100° C.; and/or the first droplets further include a second fluorocarbon having a boiling point of no more than 0° C.

4 . The emulsion of claim 1 , wherein the at least one first surfactant and/or the at least one second surfactant is/are selected from the group consisting of a dendrimer of Dendri-TAC type, an oligomer of F i TAC n or H i TAC n type, and a mixtures thereof.

5 . The emulsion of claim 1 , wherein the at least one first fluorocarbon is a perfluorocarbon.

6 . The emulsion of claim 5 , wherein the PFC is selected from the group consisting of perfluoropentane (PFP), perfluorohexane (PFH), and a mixtures thereof.

7 . The emulsion of claim 1 , wherein:
the first diameter is comprised between more than 200 nm and 600 nm; and/or the second diameter is comprised between 20 nm and 95 nm.

8 . The emulsion of claim 1 , wherein:
the first droplets have a PDI of no more than 0.5; and/or the second droplets have a PDI of no more than 0.5; wherein the PDI of the first droplets and the PDI of the second droplets are measured by dynamic light scattering (DLS).

9 . The emulsion of claim 1 , wherein the at least one solvent is selected from the group consisting of lipophilic compounds, fluorocarbons, aa mixtures thereof.

10 . The emulsion of claim 1 , wherein the at least one solvent comprises a PFC selected from the group consisting of perfluorooctane, perfluorononane, perfluorodecalin, perfluorooctyl bromide (PFOB), perfluoro-15-crown-5-ether (PFCE), 1,1,1-tris(perfluorotert-butoxymethyl)ethane (TPFBME), and mixtures thereof.

11 . The emulsion of claim 9 , wherein the at least one solvent comprises a lipophilic compound selected from the group consisting of mono-, di-, or tri-esters of glycerol or derivatives thereof, mono-, di-, tri- or tetra-esters of citric acid or derivatives thereof, fatty acids, monoesters of fatty acids, sterol esters, sphingolipids, glycerophospholipids, polyketides, saccharolipids, terpenes, lipid derivatives of prenol, and mixtures thereof.

12 . A method for providing a brain therapy, the method comprising providing the emulsion of claim 1 to a brain.

13 . The method of claim 12 , further comprising treating a disease affecting the brain,
wherein the treating comprises controlling release/delivery of the at least one drug contained in the second droplets into a brain tissue, wherein the controlling the release/delivery of the at least one drug is triggered by an external stimulus comprising ultrasounds.

14 . The method of claim 12 , further comprising treating a disease affecting the brain, wherein:
the disease is selected from the group consisting of neurodegenerative disorders, brain tumors, and combinations thereof; and/or the at least one drug is selected from the group consisting of riluzole, anacardic acid, docetaxel (DTX), paclitaxel (PTX), temozolomide, fluorouracil (5-FU), Protoporphyrin IX (PP9), and combinations thereof.

15 . A dry formulation obtained by drying the emulsion of claim 1 .

16 . A method for delivering a drug into a brain tissue, comprising the following steps:
administering the emulsion as defined in claim 1 into a blood vasculature of a brain tissue to be treated; applying a first focused ultrasound beam for a predetermined insonation time to at least one zone of the brain tissue, thereby inducing vaporization of the first droplets into bubbles; applying a second focused ultrasound beam for a predetermined insonation time to the at least one zone of the brain tissue, thereby inducing volume oscillation of the bubbles, and thus allowing localized transient brain blood barrier (BBB) opening and penetration of the second droplets into the brain tissue; and applying a third focused ultrasound beam to the at least one zone of the brain tissue, thereby triggering a controlled delivery of the at least one drug contained in the second droplets into the brain tissue.

Assignees

• Avignon Univ
• Centre Nat Rech Scient
• Inst Nat Sante Rech Med
• Univ Sorbonne
• Univ Tours
• Univ De Paris Cite

Inventors

• Urbach Wlodzimierz
• Desgranges Stéphane
• Ramesh Rashmi
• Taulier Nicolas
• Escoffre Jean-Michel
• Contino-Pepin Christiane

Classifications

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K47/06

  Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite · CPC title

• A61K41/0047

  Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent · CPC title

• A61K31/60

  Salicylic acid; Derivatives thereof · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title